L Arenare, C Porta, D Barberio, S Terzolo, V Zagonel, S Pisconti, L Del Mastro, C Pinto, D Bilancia, S Cinieri, M Rizzo, G Migliaccio, V Montesarchio, L Del Campo, F De Lorenzo, E Iannellil, L Gitto, C M Vaccaro, L Frontini, D Giannarelli, J Bryce, M L Iacovino, M C Piccirillo, C Jommi, F Efficace, S Riva, M Di Maio, C Gallo, F Perrone
{"title":"Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients.","authors":"L Arenare, C Porta, D Barberio, S Terzolo, V Zagonel, S Pisconti, L Del Mastro, C Pinto, D Bilancia, S Cinieri, M Rizzo, G Migliaccio, V Montesarchio, L Del Campo, F De Lorenzo, E Iannellil, L Gitto, C M Vaccaro, L Frontini, D Giannarelli, J Bryce, M L Iacovino, M C Piccirillo, C Jommi, F Efficace, S Riva, M Di Maio, C Gallo, F Perrone","doi":"10.1016/j.jcpo.2025.100645","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Financial toxicity (FT) is a growing issue for cancer patients worldwide. The PROFFIT questionnaire was developed in Italy to measure FT and identify its determinants in cancer patients within a public health system.</p><p><strong>Methods: </strong>A prospective study was conducted with 221 cancer patients from 10 Italian centres between March 2021 and July 2022 to validate the PROFFIT questionnaire in patients undergoing active treatment. The PROFFIT and EORTC-QLQ-C30 questionnaires were administered. Statistical analyses were performed on the PROFFIT-score (items 1-7), the financial difficulties item (Q28), and the global health status/quality of life (HR-QOL) scale from the EORTC-QLQ-C30. Geographic disparities were also analysed.</p><p><strong>Results: </strong>A total of 1149 questionnaires were completed (83 % paper-based, 17 % electronically). The median observation period was 5 months (IQR 4.5-5.8). Missing phenomenon increased over time but was not affected by the baseline PROFFIT-score. PROFFIT-score remained stable throughout treatment, with patients in Southern Italy reporting higher (worse) values. Significant associations (p < 0.0001) were found between PROFFIT-score and Q28 at all time-points. Moderate inverse correlations were observed between PROFFIT-score and HR-QOL.</p><p><strong>Conclusions: </strong>PROFFIT shows strong longitudinal validity for assessing FT in cancer patients. PROFFIT-score does not significantly change during treatment, but regional disparities highlight the need for targeted interventions, particularly in underserved areas. Further research will define cut-off values and explore FT dynamics across different patient populations.</p><p><strong>Policy summary: </strong>PROFFIT validation analyses make the instrument suitable to measure FT in cancer patients within public health systems. In addition, it may represent a valuable tool to plan specific local health policies being sensible to macro-regional variability. Finally, on the long run, it might be useful to test the impact of policies implemented against FT.</p>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":" ","pages":"100645"},"PeriodicalIF":2.0000,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Policy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jcpo.2025.100645","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Financial toxicity (FT) is a growing issue for cancer patients worldwide. The PROFFIT questionnaire was developed in Italy to measure FT and identify its determinants in cancer patients within a public health system.
Methods: A prospective study was conducted with 221 cancer patients from 10 Italian centres between March 2021 and July 2022 to validate the PROFFIT questionnaire in patients undergoing active treatment. The PROFFIT and EORTC-QLQ-C30 questionnaires were administered. Statistical analyses were performed on the PROFFIT-score (items 1-7), the financial difficulties item (Q28), and the global health status/quality of life (HR-QOL) scale from the EORTC-QLQ-C30. Geographic disparities were also analysed.
Results: A total of 1149 questionnaires were completed (83 % paper-based, 17 % electronically). The median observation period was 5 months (IQR 4.5-5.8). Missing phenomenon increased over time but was not affected by the baseline PROFFIT-score. PROFFIT-score remained stable throughout treatment, with patients in Southern Italy reporting higher (worse) values. Significant associations (p < 0.0001) were found between PROFFIT-score and Q28 at all time-points. Moderate inverse correlations were observed between PROFFIT-score and HR-QOL.
Conclusions: PROFFIT shows strong longitudinal validity for assessing FT in cancer patients. PROFFIT-score does not significantly change during treatment, but regional disparities highlight the need for targeted interventions, particularly in underserved areas. Further research will define cut-off values and explore FT dynamics across different patient populations.
Policy summary: PROFFIT validation analyses make the instrument suitable to measure FT in cancer patients within public health systems. In addition, it may represent a valuable tool to plan specific local health policies being sensible to macro-regional variability. Finally, on the long run, it might be useful to test the impact of policies implemented against FT.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
